Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    BioNTech SE

    NASDAQ: BNTX · Real-Time Price · USD
    110.00
    1.74 (1.61%)
    At close: Jul 03, 2025, 3:53 PM
    109.90
    -0.09%
    After-hours: Jul 03, 2025, 03:53 PM EDT
    1.61%
    Bid 108.36
    Market Cap 26.44B
    Revenue (ttm) 2.75B
    Net Income (ttm) -768.64M
    EPS (ttm) -3.66
    PE Ratio (ttm) -30.05
    Forward PE -18.86
    Analyst Buy
    Ask 110.88
    Volume 613,272
    Avg. Volume (20D) 1,182,400
    Open 107.86
    Previous Close 108.26
    Day's Range 107.83 - 111.82
    52-Week Range 76.53 - 131.49
    Beta 1.28

    About BNTX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol BNTX
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for BNTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    BioNTech SE is scheduled to release its earnings on Aug 4, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    +18.05%
    BioNTech shares are trading higher after the compa... Unlock content with Pro Subscription
    1 month ago
    +4.01%
    Shares of vaccine stocks are trading higher following a report indicating FDA advisers will consider if COVID-19 vaccines should target the LP.8.1 subvariant for 2025-2026.
    news image

    3 weeks ago · schaeffersresearch.com

    CureVac Stock Soars on BioNTech Buyout

    Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that  BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.

    news image

    3 weeks ago · benzinga.com

    BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

    BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.

    news image

    3 weeks ago · proactiveinvestors.com

    BioNTech boosts cancer mRNA pipeline with CureVac acquisition

    BioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA vaccine developer, in an all-stock deal valued at approximately $1.25 billion. Under the deal terms, e...

    news image

    3 weeks ago · barrons.com

    BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.

    CureVac stock soared 29% $5.26 in premarket trading immediately following the news.

    news image

    3 weeks ago · reuters.com

    BioNTech to acquire CureVac in $1.25 billion all-stock deal

    German biotech firm BioNTech said on Thursday it agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares to boost its work on new mRNA-based cancer treatments.

    news image

    3 weeks ago · cnbc.com

    RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say

    Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trus...

    news image

    3 weeks ago · reuters.com

    Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up

    Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccin...

    news image

    3 weeks ago · barrons.com

    Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

    Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.

    news image

    3 weeks ago · investors.com

    Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr.

    Vaccines stocks slipped late Monday after HHS fired all members of a CDC committee in charge of making vaccine suggestions.

    news image

    3 weeks ago · seekingalpha.com

    Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment

    Bristol-Myers Squibb is attractively valued, offers a 5%+ dividend yield, and benefits from a strong oncology pipeline after its BioNTech deal. The $11B BioNTech partnership gives BMY access to BNT327...

    Add to Watchlist